Summit Therapeutics
SMMT
238 hedge funds and large institutions have $2.08B invested in Summit Therapeutics in 2025 Q2 according to their latest regulatory filings, with 73 funds opening new positions, 66 increasing their positions, 75 reducing their positions, and 45 closing their positions.
64% more call options, than puts
Call options by funds: $126M | Put options by funds: $77.1M
62% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 45
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
12% more funds holding
Funds holding: 212 → 238 (+26)
9% more capital invested
Capital invested by funds: $1.91B → $2.08B (+$173M)
0.21% less ownership
Funds ownership: 13.39% → 13.18% (-0.21%)
12% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 75
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$212M |
| 2 |
ACL
APEIRON Capital Ltd
Hong Kong
|
+$27.4M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$22.8M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.9M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$67.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$60.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$38.8M |
| 4 |
BlackRock
New York
|
-$35.4M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$24.4M |
SMMT Hedge Fund Activity: Q2 2025 in Review
238 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2025, worth a combined $2.08B — up 9.1% from $1.91B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new SMMT positions and 45 closed out — a net gain of 28 holders — while 66 added to existing stakes and 75 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $212M. The largest seller was Vanguard Group, cutting an estimated $67.7M.
- 238 institutional investors held Summit Therapeutics (SMMT) as of Q2 2025, up from 212 in Q1 2025.
- Funds reported $2.08B of Summit Therapeutics stock for Q2 2025, up 9.1% quarter-over-quarter.
- 73 funds opened new Summit Therapeutics positions in Q2 2025 and 45 closed out, a net change of +28 holders.
- The largest Summit Therapeutics buyer in Q2 2025 was Baker Bros. Advisors, an estimated $212M added.
- The largest Summit Therapeutics seller in Q2 2025 was Vanguard Group, an estimated $67.7M sold.
Based on aggregated 13F filings for Q2 2025.